FINAL PROGRAM - sepsis-update.de

10th International Congress

SEPSIS & COVID-19

FINA

L PROG

RAM

ImprintDeutsche Sepsis-Gesellschaft e.V.Am Klinikum 1 • 07747 Jena, GermanyTel.: +49 3641 939 66 87

Design: © Lindgrün GmbH | 2021www.lindgruen-gmbh.com

PREFACE 4

GENERAL INFORMATION 6

ENDORSEMENTS 8

SCHEDULE AT A GLANCE 10

PROGRAM 16Wednesday 17Thursday 24Friday 30

SPEAKERS & CHAIRS 36

COMPANIES & EXHIBITORS 46

4 Preface Preface 5

According to the World Health Organization (WHO), approx. 5% of symptomatic patients with a SARS-CoV-2 infection develop a critical COVID-19 disease with respiratory failure, shock, or multiorgan dysfunction and 14% develop a severe disease with dyspnea, hypoxia, or more than 50% lung involvement on imaging.

This is, why we have decided to give COVID-19 research a place it deserves in intensive care medicine. The COVID-19 pandemic dominates the research agenda of intensive care physicians, microbiologists, immunolo-gists and epidemiologists worldwide. While the traditional respiratory management of acute lung failure was in the foreground at the beginning of the pandemic, the patho-physiology of COVID-19 associated ARDS is now increa-singly better understood. It became clear that beyond a systemic response there is a more compartmentalized inflammatory response in COVID-19 and adjuvant immu-nomodulatory strategies might improve outcome.

While prevention and vaccination strategies are currently in the foreground of (research) political and media agendas, clinical research for an evidence-based management of severe and critical COVID-19 disease is rather neglected. As of November 2020, 2,024 trials (separable into 2,895 individual treatment arms), encom- passing total enrolment in excess of 500,000 patients had been registered (▶ see “Trends in COVID-19 therapeutic clinical trials”). However, ~5 % could be considered randomized and adequately powered, and only about a quarter of enrolled patients contributed to adequately powered and well-controlled trials.

There is no progress in this pandemic without national and international research cooperation in phase III trials. This is why the major breakthroughs in treatment were created by three large investigator-initiated study groups that are unprecedented in the history of modern critical care medicine: SOLIDARITY from the WHO, RECOVERY from NHS England and REMAP-CAP from the EU, Canada, Australia and the US. Furthermore, the National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines. These study groups recruited ten thousands of patients in record time under the most difficult of conditions. The leading representatives of these study groups will report on the latest results of their work in Weimar.

Furthermore, results from phase II/III treatment and vaccination studies of the pharmaceutical industry, as well as results by diagnostic companys are expected by September 2021 and will be presented. Another focus of our congress will be the Surviving Sepsis Guidelines 2021, which are about to be completed.

Get up to date on the current state of knowledge, top publications from top researchers in basic and clinical research. We plan the congress as a face-to-face event, because that is our characteristic – get together, discuss without limits and enjoy!

Markus Weigand Frank M. Brunkhorst Chair GSS Secretary General GSS

WELCOME TO THE 10TH WEIMAR SEPSIS UPDATE OF THE GERMAN SEPSIS SOCIETY!

6 General Information General Information 7

Scientific Committee Prof. M. Adamzik, Bochum Prof. F.M. Brunkhorst, Jena Prof. A. Kaasch, Magdeburg Prof. M. Pletz, Jena Prof. M. Weigand, Heidelberg

Scientific OrganisationProf. F.M. BrunkhorstSecretary general of the German Sepsis SocietyE-mail: [email protected]

Secretary: A. PesterPhone +49 3641 9396687E-mail: [email protected]

Congress Language• English

Organizerweimar GmbHGesellschaft für Wirtschaftsförderung, Kongress- und TourismusserviceUNESCO-Platz 199423 Weimar, Germany

CMEThe meeting is certified by the State Medical Chamber of Thuringia with advanced training points.

General information

Über dem

Kegeltor

Jorge-Semprùn-Platz

Coudraystraße

Hauptbahnhof

weimarhalle

Schopenhauerstraße

Carl-August-Allee

K.-L

iebk

nech

t-St

raße

Frie

dric

h-Eb

ert-

Stra

ße

Friedensstraße

Schwanseestraße

Erfurter Straße

Ernst-Thälmann-Straße

Graben

Congress venuecongress centrum neue weimarhalleUNESCO-Platz 199423 Weimar, Germany

www.weimarhalle.de

8 General Information

SCHED

ULE

AT A

GLA

NCE

Endorsements

▶ Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS), Sydney

▶ Center for Sepsis Control and Care (CSCC), Jena University Hospital

▶ Canadian Critical Care Trials Group (CCCTG), Toronto

▶ Central and Eastern European Sepsis Forum (SepsEast)

▶ Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN), Berlin

▶ Deutsches Zentrum für Lungenforschung e.V. (DZL), Gießen

▶ European Group on Immunology of Sepsis (EGIS), Jena

▶ European Shock Society (ESS)

▶ Intensive Care National Audit and Research Centre (ICNARC), and Imperial College London

▶ International Forum for Acute Care Trialists (INFACT), Toronto

▶ Irish Critical Care Clinical Trials Network (ICCCTN), Dublin

▶ REMAP-CAP (A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia), Utrecht

▶ UK Critical Care Research Group (UKCCRG)

▶ University Medical Center Utrecht (UMCU)

10 Schedule at a glance Schedule at a glance 11

Time Large hall Wing hall 1 Wing hall 2 Small hall Seminar room 1 Seminar room 2

07:30 – 08:00

08:00 – 08:30

08:30 – 09:00

09:00 – 09:30 Workshop Please follow the signs on site

Workshop Please follow the signs on site



Workshop Please follow the signs on site09:30 – 10:00

10:00 – 10:30

10:30 – 11:00

11:00 – 11:30

11:30 – 12:00

12:00 – 12:30Press Conference12:30 – 13:00 Lunch

13:00 – 13:30 Opening SessionBeyond the Pandemic 1 – Research platforms & networks

13:30 – 14:00

14:00 – 14:30

14:30 – 15:00

15:00 – 15:30

15:30 – 16:00

16:00 – 16:30 Session 1Beyond the pandemic 2 – COVID-19 clinical registries

16:30 – 17:00

17:00 – 17:30

17:30 – 18:00 Session 2Beyond the pandemic 3 – COVID-19 basic insights

18:00 – 18:30

18:30 – 19:00

from 19:00 Get-Together-Party

Industrial exhibition10:00 am – 5:00 pm

The congress is generously supported by a broad range of companies. Please visit the industrial exhibition!

Wednesday September 8, 2021

Sessions Workshops Lunch symposia PressSocialPoster sessions


Time Large hall Wing hall 1Wing hall 2 / Small hall Seminar room 1 Seminar room 2 Eastern foyer

07:30 – 08:00

08:00 – 08:30 Session 3Beyond the pandemic 4 – Steroids08:30 – 09:00

09:00 – 09:30

09:30 – 10:00 Session 4Beyond the pandemic 5 – Ventilation strategies10:00 – 10:30

10:30 – 11:00Session 5Beyond the pandemic 6 – Immunmodulators

11:00 – 11:30

11:30 – 12:00 Lunch Wing hall 2

12:00 – 12:30 Lunch Symposium SOBI

Lunch Symposium Pfizer

Lunch Symposium Thermo Fisher Scientific

Lunch Symposium SphingoTec / Adrenomed

PS 1: Animal models

12:30 – 13:00 PS 2: Ventilation / ECMO

13:00 – 13:30 PS 3: EGIS

13:30 – 14:00

14:00 – 14:30 Session 6Beyond the pandemic 7 – Antivirals14:30 – 15:00

15:00 – 15:30

15:30 – 16:00 Session 7Beyond the pandemic 8 – Anticoagulants & Antibodies16:00 – 16:30

16:30 – 17:00

17:00 – 17:30 Session 8Beyond the pandemic 9 – Antiinflammation & ACE-inhibiton17:30 – 18:00

18:00 – 18:30 Member MeetingDSG General Assemblymembers only18:30 – 19:00

Thursday September 9, 2021



Sessions Workshops Lunch symposia Press Member meetingsPoster sessions Social

Member Meeting: Small hall

REMAP-CAP ITSC Meetingmembers only


Time Large hall Wing hall 1 Wing hall 2 Seminar room 1 Seminar room 2 Eastern foyer

07:30 – 08:00

08:00 – 08:30 Session 9Beyond the pandemic 10 – Long-term morbidity08:30 – 09:00

09:00 – 09:30

09:30 – 10:00 Session 10Sepsis 1 – evidence from recent RCTs 110:00 – 10:30

10:30 – 11:00Session 11Sepsis 2 – evidence from recent RCTs 2

11:00 – 11:30

11:30 – 12:00 Lunch

12:00 – 12:30 Lunch Symposium CytoSorbents

Lunch Symposium Inflammatix

Lunch Symposium Radiometer

Lunch Symposium Gilead

PS 4: Sepsis

12:30 – 13:00

13:00 – 13:30

13:30 – 14:00

14:00 – 14:30 Hot Topic Session

14:30 – 15:00

15:00 – 15:30

15:30 – 16:00

16:00 – 16:30

16:30 – 17:00

17:00 – 17:30

17:30 – 18:00

18:00 – 18:30

18:30 – 19:00

from 19:00



Friday September 10, 2021

Sessions Workshops Poster sessions Lunch symposia PressSocial

Program 17

Wednesday September 8, 2021

PROG

RAM

09:00 – 12:00 | please follow the signs on site

Workshops (parallel sessions)

09:00 – 12:00WS1: Animal models in sepsis and COVID-19 Coordination: Osuchowski M, Vienna; Skirecki T, Warszaw

Modeling of COVID-19: a developing success storyOsuchowski M, Vienna

Murine models of viral pneumonia – from the flu to COVID-19Knapp S, Vienna

Tissue damage control in COVID-19: the role of parenchymaWeis S, Jena

Modeling bacterial pneumonia: on the road to translationSkirecki T, Warsaw

Pulmonary capillary leakage – from mice and menDavid S, Zürich

Free oral presentations Obesity contributes to severe viral pneumonia infection course in DIO miceHornung F, Jena

Anserin reduces MG-induced mortality in experimental Sepsis restoring endothelial integrityGallenstein N, Heidelberg

Ex vivo monocyte cytokine responses are not a proxy for the in vivo cytokine response during experimental human endotoxemiaBruse N, Nijmegen

Hyperspectral Imaging for Bedside Evaluation of Microcirculatory Tissue Oxygenation and Perfusion QualityDietrich M, Heidelberg

18 Program Program 19

Targeted rescue of synaptic plasticity improves cognitive decline in sepsis-associated encephalopathyGeis C, Jena

09:00 – 12:00WS2: European Group on Immunology of Sepsis (EGIS) Coordination: Bermejo-Martin JF, Valladolid; Rubio I, Jena

Severe COVID-19 and bacterial sepsis: variations on a theme or unique disease entities?Kox M, Nijmegen

Immunopathogenesis of COVID-19: lessons to learn from special patientsCossarizza A, Modena

IL6: a therapeutic target in COVID-19?Shankar-Hari M, London

The link between uncontrolled viral replication and host dysregulated response in severe COVID-19Bermejo-Martin J, Salamanca

T lymphocyte response in critically ill COVID-19 patientsVenet F, Lyon

SARS-CoV-2 organ tropism and the senescence-associated viral responseDeinhardt-Emmer S, Jena

Free oral presentations Properties of proenkephalin in septic acute kidney injuryNusshag C, Heidelberg

Activated microglia mediate neurocognitive deficits in severe sepsisWickel J, Jena

09:00 – 12:00WS3: Deutsches Netzwerk Universitätsmedizin COVID-19 Coordination: Boor P, Aachen; Witzenrath M, Berlin

NAPKONVehreschild J, Cologne

COVIMKlein F, Cologne

AKTINSchirrmeister W, Magdeburg

DEFEAT PANDEMIcsBoor P, Aachen

CODEXWalcher F, Magdeburg; Nauck M, Greifswald

Organo-StratHocke A, Berlin

RACOONPenzkofer T, Berlin

09:00 – 12:00WS4: Extracorporeal Life Support (ECLS) and Extracorporeal Membrane Oxygenation (ECMO) in sepsis- and COVID-19 associated ARDS Coordination: Karagiannidis C, Cologne; Szułdrzyński K, Cracow

1. ECMO and COVID-19 Epidemiology of COVID-19 ECMO outcome: regional differences Karagiannidis C, Cologne

Reasons for differences in outcome: Age? Resources? Money?Broman LM, Stockholm

Wednesday September 8, 2021 Wednesday September 8, 2021



Does anticoagulation make a difference and account for outcome in COVID19?Grasselli G, Milan

2. ECMO and general ICU treatment The right indication for ECMOWeber-Carstens S, Berlin

Mechanical ventilation on vv-ECMOCamporota L, London

Long term quality of life in ARDS and ECMO survivorsNN

3. ECMO: novel techniques and development ECMO and extracorporeal blood purification in COVID-19Supady A, Freiburg

Lung transplantation for COVID-19-associated single organ failure?NN

VV ECMO versus hybrid configurations – added benefit or fancy complexity? Szuldrzynski K, Kraków

Selected free oral presentations

09:00 – 12:00WS5: SepsEast – Experiences with the pandemic in East European countries Coordination: Beneš J, Prague; Mikaszewska-Sokolewicz M, Warsaw; Kluge S, Hamburg

Participants:• Hungary: Molnár Z, Szeged• Romania: Săndesc D, Timișoara• Serbia: Jankovic R, Niš• Poland: Jankowksy M, Cracow

• Czech Republic: Beneš J, Prague• Slovak Republic: Záhorec R, Bratislava• Slovenia: Lainscak M, Ljubljana• Croatia: Šustić A, Rijeka

13:00 – 15:30 | Large hall

Opening Session Beyond the Pandemic 1 – Research platforms & networks

Chair: Weigand M, Heidelberg; Welte T, Hannover

Key Note Lecture A.I. systems managing sepsis - hope or hype? Gordon A, London

Research Awards CeremonyGerman Sepsis Society Awards 2021Weigand M, Heidelberg, Pletz M, Jena

SOLIDARITY – how the WHO organizes global research on COVID-19 treatmentsMurthy S, Vancouver

REMAP-CAP – a role model for global clinical research in the critically illWebb S, Sydney

REMAP-CAP / RECOVERY: how UK organises high-quality clinical trials in the pandemic Rowan K, London

NUM – a publicy funded research network of German university hospitalsHeyder R, Berlin



16:00 – 17:20 | Large hall

Session 1 Beyond the pandemic 2 – COVID-19 clinical registries

Chair: Szakmany T, Cardiff; Scherag A, Jena

ISARIC – a global patient registry Merson L, London

ICNARC – a national patient registry Rowan K, London

DIVI – a German ICU registry Karagiannidis C, Cologne

Personalized medicine – phenotype anarchy or promise realized? Seymour CW, Pittsburgh

17:20 – 17:40

Break

17:40 – 19:00 | Large hall

Session 2Beyond the pandemic 3 – COVID-19 basic insights

Chair: Bauer M, Jena; Briegel J, Munich

Compartimentalized vs systemic inflammation Shankar-Hari M, London

Endothelial dysfunction van de Veerdonk F, Nijmegen

Host genetics Kox M, Nijmegen

Pulmonary dysfunction Welte T, Hannover

19:00 | Weimarhalle terraces

Get-Together-Partyfeaturing „Travelling Lights“, Berlin

15:30 – 16:00

Break

Foto: Sepsis Update 2019

Maik Schuck (c) weimar GmbH


Thursday September 9, 2021Thursday September 9, 2021

08:00 – 09:00 | Large hall

Session 3 Beyond the pandemic 4 – Steroids

Chair: Gerlach H, Berlin; Adamzik M, Bochum

Current evidence from RCTs Gordon T, London

Dose and treatment duration Myatra SN, Mumbai

Responders vs. non-responders Annane D, Paris

09:00 – 09:30

Break

09:30 – 10:30 | Large hall

Session 4 Beyond the pandemic 5 – Ventilation strategies

Chair: Stehr S, Leipzig; Weigand M, Heidelberg

Prone positioning Gattinoni L, Göttingen

Ventilation strategies Nichol A, Dublin

ECMO Weber-Carstens S, Berlin

10:30 – 10:45

Break

11:45 – 12:00

Break

10:45 – 11:45 | Large hall

Session 5 Beyond the pandemic 6 – Immunmodulators

Chair: Singer M, London; Herold S, Giessen

Interleukin-6 receptor antagonists - current evidence Derde L, Utrecht

Anakinra in severe COVID-19 Marshall J, Toronto

suPAR-guided Anakinra treatment Giamarellos-Bourboulis EJ, Athens

12:00 – 13:30 | Eastern foyer

Poster sessions

12:00 – 12:30Poster session 1: Animal models Chairs: Osuchowski M, Vienna; Skirecki T, Warsaw

12:30 – 13:00Poster session 2: Ventilation / ECMO Chairs: Karagiannides C, Cologne; Szułdrzyński K, Kraków

13:00 – 13:30Poster session 3: EGIS Chairs: Rubio I, Jena; Bermejo-Martin J, Valladolid



12:00 – 13:30

Lunch symposia

COVID-19 and beyond: Complex challenges for infection management in hospitalsWing hall 1 Supported by Pfizer Pharma GmbHChair: Cornely O, Cologne

WelcomeCornely O, Cologne

COVID-19 complications: who gets a CAPA?Cornely O, Cologne

MRGN infections in the current context: what is new?Hagel S, Jena

Diagnostic stewardship: still theory or already reality?Becker S, Saarbrücken

Panel discussionModeration: Cornely O, Cologne

Antibiotic stewardship in acute infectious disease patients and in the follow-upSeminar room 1 Supported by Thermo Fisher ScientificModeration: Pletz M, Jena; Welte T, Hannover

Rational antibiotic therapy in oncologyvon Lilienfeld-Toal M, Jena

Specifics of antibiotic stewardship in surgical patientsEckmann C, Hann. Münden

Early cytokine blockade in COVID-19 pneumoniaLarge hall Supported by Swedish Orphan Biovitrum GmbHChair: Giamarellos-Bourboulis E, Athen; Welte T, Hannover

WelcomeGiamarellos-Bourboulis E, Athen

Cytokine storm in COVID-19: Lessons learnt? Implications for therapeutic management.Welte T, Hannover

Immune stratification of COVID-19 patients: Which biomarkers can guide treatment decision? Netea M, Nijmegen

Prevent the storm: SAVE MORE – Early IL-1 inhibition in COVID-19 pneumonia.Giamarellos-Bourboulis E, Athen

Discussion & SummaryWelte T, Hannover



15:00 – 15:30

Break

14:00 – 15:00 | Large hall

Session 6 Beyond the pandemic 7 – Antivirals

Chair: Kaasch A, Magdeburg; Salzberger B, Regensburg

Interferons Arabi Y, Riad

Remdesivir Pletz M, Jena

Ivermectin Haniffa R, Oxford

17:00 – 18:00 | Large hall

Session 8 Beyond the pandemic 9 – Antiinflammation & ACE-inhibiton

Chair: Brenner T, Essen; Weis S, Jena

High-dose vitamin C Adhikari N, Toronto

Simvastatin McAuley D, Belfast

RAS-targeted therapies Lawler P, Toronto

13:30 – 14:00

Break

Precision Medicine in Septic Organ Failure: Biomarker-guided Diagnosis and TherapySeminar room 2 Supported by SphingoTec GmbH / Adrenomed AGChair: Weigand M, Heidelberg

Implementing new Biomarkers in Daily Practice – Proenkephalin and biologically active Adrenomedullin in SepsisMartin L, Aachen

Biomarker-guided Approach for the Treatment of Septic Shock – Precision Medicine in the AdrenOSS-2 Study Schürholz T, Aachen

15:30 – 16:30 | Large hall

Session 7 Beyond the pandemic 8 – Anticoagulants & Antibodies

Chair: David S, Zürich; Nierhaus A, Hamburg

Heparins – current evidence from RCT´s Zarychanski R, Winnipeg

Antiplatelets Bradbury C, Bristol

Reconvalescent plasma Estcourt L, Oxford

16:30 – 17:00

Break

20:00 – open | Villa Haar, Ilm Park

Faculty Dinner Featuring Vladimir Karparov, saxophone


Friday September 10, 2021Friday September 10, 2021

08:00 – 09:00 | Large hall

Session 9 Beyond the pandemic 10 – Long-term morbidity

Chair: Brunkhorst FM, Jena; Shankar-Hari M, London

Autoantibodies Altmann D, London

Secondary infections Russell CD, Edinburgh

Long-term consequences Sigfrid L, Oxford

12:00 – 13:30 | Eastern foyer

Poster session 4: Sepsis

Chair: Brinkmann A, Heidelberg; Hagel S, Jena

09:00 – 09:30

Break

09:30 – 10:30 | Large hall

Session 10 Sepsis 1 – evidence from recent RCTs 1

Chair: Meybohm P, Würzburg; Dembinski R, Bremen

Dexmedetomidine in sepsis Hughes CG, Nashville

Oxygenation targets for acute hypoxemic respiratory failure Klitgaard TL, Aalborg

Lower vs higher PEEP in patients without ARDS Schultz MJ, Amsterdam

10:30 – 10:45

Break

10:45 – 11:45 | Large hall

Session 11 Sepsis 2 – evidence from recent RCTs 2

Chair: Marx G, Aachen; Oppert M, Potsdam

Therapeutic drug monitoring for piperacillin in sepsis Hagel S, Jena

Timing of initiation of renal replacement therapy Zarbock A, Münster

Timing of norepinephrine initiation in patients with septic shock Singer M, London

11:45 – 12:00

Break


Friday September 10, 2021Friday September 10, 2021

12:00 – 13:30

Lunch symposia

Hemoadsorption with CytoSorb in sepsis and COVID-19 patients – an updateLarge hall Supported by CytoSorbents Europe GmbHChair: Singer M, London; Kogelmann K, Emden

Immune system alterations and organ dysfunction in sepsisShankar-Hari M, London

Effects of hemoadsorption on hemodynamic stability in septic shockMolnár Z, Budapest

Multisystem inflammatory syndrome associated with COVID-19 – how to master the challenge?Ferrer-Roca R, Barcelona

Use of hemoadsorption in COVID-19 patients – what did we learn so far?Nierhaus A, Hamburg

Sepsis and fungal infection – a causal relationship?Seminar room 2 Supported by Gilead Sciences GmbHChair: Weigand M, Heidelberg

Sepsis as a risk factor for mycosis?Wichmann D, Hamburg

Candida sepsis – new trends? Richter D, Heidelberg

“Aspergillus sepsis”: COVID-19-associated pulmonary aspergillosis (CAPA) – where do we stand? Böll B, Cologne

Interaction limits satisfaction: Practical problems in the use of antimycoticsHöhl R, Nürnberg

Think patient, not bug – how reading the host response can shape the future of acute care medicineWing hall 1 Supported by InflammatixChair: Giamarellos-Bourboulis E, Athens, Uhle F, Heidelberg

How to tame the power of systems immunology into actionable resultsNN

Sensitivity, predictive values & friends – Which characteristics we should really care about in clinical practice Gerlach H, Berlin

Prospective evaluation of host-response diagnostics in ED – the Berlin experienceBauer W, Berlin

Host-response based endotyping and prognostication of patients with COVID19 – the Greek experienceGiamarellos-Bourboulis E, Athens


Friday September 10, 2021

14:00 – 15:00 | Large hall

Hot Topic Session

Chair: Weigand M, Heidelberg; Adamzik M, Bochum

Biomarkers for antimicrobial stewardship in COVID-19 timesKox M, Nijmegen

Crystalloid composition and fluid bolus in critically ill patients - results of the BaSICS trialWeigand M, Heidelberg

Double trouble: a pandemic of obesity and COVID-19Scherag, A, Jena

13:30 – 14:00

Break

Biomarker, Guidelines, and future trends within Sepsis and COVID-19Seminar room 1 Supported by Radiometer GmbHChair: Oppert M, Potsdam

Guideline development and future trends within sepsis treatmentSinger M, London

Biomarkers: what matters if the result has to be ready fastPetersmann A, Oldenburg

Biomarker for antibiotic stewardship in sepsis and COVID-19Oppert M, Potsdam

Imagine a world saferfrom infection. We do.from infection. Imagine a world saferfrom infection. Imagine a world saferfrom infection. Imagine a world saferfrom infection. from infection. Imagine a world safer

Speakers & chairs 37

Speakers and chairsMichael Adamzik Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany

Marylyn Addo I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Neill AdhikariSunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

Danny Altmann Department of Immunology and Inflammation Imperial College London, London, United Kingdom

Djillali Annane Réanimation médicale adulte, Hôpital Raymond-Poincaré, Paris, France

Yaseen Arabi Intensive Care Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Wolfgang Bauer Zentrale Notaufnahme, Charité - Universitätsmedizin Berlin, Berlin, Germany

Michael Bauer Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Jena, Jena, Germany

Sören Becker Institut für Medizinische Mikrobiologie und Hygiene, Universität des Saarlandes, Saarbrücken, Germany

Jan Beneš Department of Anesthesiology and Intensive Care Medicine, Charles University in Prague | CUNI, Plzeň-Lochotín, Czech Republic

Jesus F. Bermejo-Martin Group for Biomedical Research in Sepsis, Hospital Clínico Universitario de Valladolid/IECSCYL, Valladolid, Spain

SPEAKERS &

CH

AIRS

38 Speakers & chairs Speakers & chairs 39

Stefanie Deinhardt-Emmer Institut für Medizinische Mikrobiologie, Universitätsklinikum Jena, Jena, GermanyRolf Dembinski Klinik für Intensivmedizin und Notfallmedizin, Klinikum Bremen Mitte, Bremen, Germany

Lennie Derde Intensive Care Medicine, UMC Utrecht, Utrecht, Netherlands

Christian Eckmann Allgemein-, Viszeral- und Thoraxchirurgie, Klinikum Hann. Münden, Hann. Münden, Germany

Lise Estcourt Clinical Trials Unit, NHS Blood and Transplant, Oxford, United Kingdom

Ricard Ferrer Roca Intensive Care Medicine, Vall d’Hebron General Hospital, Barcelona, Spain

Luciano Gattinoni Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Göttingen, Germany

Herwig Gerlach Klinik für Anästhesie, operative Intensivmedizin und Schmerz- therapie, Vivantes Klinikum Neukölln, Berlin, Germany

Evangelos J. Giamarellos-Bourboulis 4th Department of Medicine, ATTIKON University Hospital Athens, Athens, Greece

Anthony Gordon Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom

Giacomo Grasselli Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Stefan Hagel Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Germany

Boris Böll Innere Medizin I, Uniklinik Köln, Cologne, Germany

Peter Boor Institut für Pathologie, Universitätsklinikum Aachen, Aachen, Germany

Charlotte A. Bradbury Weston NHS Foundation Trust, University Hospitals Bristol, Bristol, United Kingdom

Thorsten Brenner Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Essen, Germany

Josef Briegel Klinik für Anästhesiologie, Klinikum der Universität München, Munich, Germany

Alexander Brinkmann Klinik für Anästhesie, operative Intensivmedizin und spezielle Schmerztherapie, Klinikum Heidenheim , Heidenheim, Germany

Lars Mikael Broman Department of Physiology and Pharmacology, Karolinska University Hospital, Stockholm, Sweden

Frank M. Brunkhorst Zentrum für Klinische Studien, Universitätsklinikum Jena, Jena, Germany

Luigi Camporota Critical Care Medicine, Guy‘s and St Thomas‘ NHS Foundation Trust, London, United Kingdom

Oliver Cornely Studienzentrum Infektiologie, Uniklinik Köln, Köln, Germany

Andrea Cossarizza Dipartimento di Scienze Mediche e Chirurgiche materno infantili e dell‘adulto, Università degli Studi di Modena e Reggio Emilia, Modena, Italy

Sascha David Institut für Intensivmedizin, Universitätsspital Zürich, Zürich, Switzerland


Stefan Kluge Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Sylvia Knapp Laboratory of Infection Biology, Medical University Vienna, Vienna, Austria

Klaus Kogelmann Klinik für Anästhesiologie und Intensivmedizin, Klinikum Emden, Emden, Germany

Matthijs Kox Intensive Care Medicine, Radboud University Medical Centre, Nijmegen, Netherlands

Mitja Lainscak Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenia

Patrick Lawler Institute of Medical Science, University of Toronto, Toronto, Canada

John Marshall Department of Surgery, University of Toronto, Toronto, Canada

Lukas Martin Klinik für Operative Intensivmedizin und Intermediate Care, Universitätsklinikum Aachen, Aachen, Germany

Gernot Marx Klinik für Operative Intensivmedizin und Intermediate Care, Universitätsklinikum Aachen, Aachen, Germany

Danny McAuley Dentistry and Biomedical Sciences, Queen‘s University School of Medicine, Belfast, United Kingdom

Laura Merson The Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom

Patrick Meybohm Klinik und Poliklinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und Schmerztherapie, Universitätsklinikum Würzburg, Würzburg, Germany

Rashan Haniffa Anaesthetics Department, University College London, London, United Kingdom

Susanne Herold Medizinische Klinik II, SP Infektiologie, Universitätsklinikum Gießen, Gießen, Germany

Ralf Heyder Stabsstelle Externe Vernetzung und Strategische Kooperationen, Charité - Universitätsmedizin Berlin, Berlin, Germany

Andreas Hocke Med. Klinik m.S. Infektiologie und Pneumologie, Molekulare Bildgebung, Charité - Universitätsmedizin Berlin, Berlin, Germany

Rainer Höhl Institut für Klinikhygiene, Medizinische Mikrobiologie und Klinische Infektiologie, Klinikum Nürnberg Nord, Nuremberg, Germany

Christopher Hughes Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, USA

Radmilo J. Jankovic Anesthesiology and Reanimation Center, Clinical Center Niš, Niš, Serbia

Miłosz Jankowski Internal Medicine, Jagiellonian University Kraków, Kraków, Poland

Achim Kaasch Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Universitätsmedizin Magdeburg, Magdeburg, Germany

Christian Karagiannidis Lungenklinik, Krankenhaus Köln-Merheim, Cologne, Germany

Florian Klein Institut für Virologie, Uniklinik Köln, Cologne, Germany

Thomas Lass Klitgaard Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark


Kathy Rowan Chief Investigator, ICNARC, London, United Kingdom

Ignacio Rubio FZL - FB Experimentelle Anästhesie, Universitätsklinikum Jena, Jena, Germany

Clark D Russell Infection Medicine, The University of Edinburgh, Edinburgh, United Kingdom

Dorel Sandesc Anestezie, Brol Medical Center, Timisora, Romania

André Scherag Institut für Medizinische Statistik, Informatik und Datenwissen-schaften, Universitätsklinikum Jena, Jena, Germany

Wiebke SchirrmeisterUniversitätsklinik für Unfallchirurgie, Otto-von-Guericke-Universität Magdeburg, Magdeburg

Marcus J. Schultz Intensive Care Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands

Christopher W. Seymour Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, USA

Manu Shankar-Hari Department of Critical Care Medicine, King‘s College London, London, United Kingdom

Louise Sigfrid Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom

Mervyn Singer Bloomsbury Institute for Intensive Care Medicine, University College Hospital, London, United Kingdom

Tomasz Skirecki Department of Anesthesiology and Intensive Care, Centre of Postgraduate Medical Education, Warsaw, Poland

Malgorzata Mikaszewska-Sokolewicz Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland

Zsolt Molnár Department of Anesthesiology and Intensive Care, University of Szeged, Faculty of Medicine, Szeged, Hungary

Srinivas Murthy Department of Pediatrics, University of British Columbia, Vancouver, Canada

Sheila N. Myatra Department of Anesthesiology, Critical Care and Pain, Tata Memorial Hospital, Mumbai, India

Alistair Nichol Critical Care Medicine, University College Dublin, Dublin, Ireland

Axel Nierhaus Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Michael Oppert Klinik für Notfall- und Internistische Intensivmedizin, Klinikum Ernst von Bergmann, Potsdam, Germany

Marcin Osuchowski Experimentelle und Klinische Traumatologie, Ludwig-Boltzmann-Institut, Wien, Austria

Tobias Penzkofer Klinik für Radiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany

Astrid Petersmann Institut für Klinische Chemie und Laboratoriumsmedizin, Klinikum Oldenburg, Oldenburg, Germany

Mathias Pletz Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Germany

Daniel Richter Klinik für Anästhesiologie, Universitätsklinikum Heidelberg, Heidelberg, Germany


Markus Weigand Anästhesiologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany

Sebastian Weis Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Germany

Tobias Welte Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany

Dominic Wichmann Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Martin Witzenrath Medizinische Klinik m. S. Infektiologie und Pneumologie, Charité – Universitätsmedizin Berlin, Berlin, Germany

Roman Záhorec Department of Anesthesiology and Intensive Medicine, Comenius University Bratislava, Bratislava, Slovakia

Alexander Zarbock Klinik für Anästhesiologie, operative Intensivmedizin und Schmerz-therapie, Universitätsklinikum Münster, Münster, Germany

Ryan Zarychanski Department of Medicine and Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada

Sebastian Stehr Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Leipzig, Leipzig, Germany

Alexander Supady Klinik für Kardiologie und Angiologie, Universitätsklinikum Freiburg, Herzzentrum, Freiburg, Germany

Alan Šustić Department of Anesthesiology, Resuscitation and Intensive Care, University of Rijeka, Rijeka, Croatia

Tamás Szakmany Cardiff University School of Medicine, Director of Critical Illness Research, Cardiff, United Kingdom

Konstanty Szułdrzyński Klinika Alergii i Immunologii, Uniwersytet Jagielloński Collegium Medicum, Kraków, Poland

Florian Uhle Institut für Immunologie, Universitätsklinikum Heidelberg, Heidelberg, Germany

Frank van de Veerdonk Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands

Janne Vehreschild Innere Medizin I, Uniklinik Köln, Cologne, Germany

Fabienne Venet Immunology Laboratory, Hôpital E. Herriot - Hospices Civils de Lyon, Lyon, France

Marie von Lilienfeld-Toal Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany

Steve Webb School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

Steffen Weber-Carstens Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Charité – Universitätsmedizin Berlin, Berlin, Germany

Companies & exhibitors 47

Lunch symposia

COM

PAN

IES &

EXH

IBITORS

▶ CytoSorbents Europe GmbH // 17.000€

▶ Swedish Orphan Biovitrum GmbH // 17.000€

▶ Adrenomed AG & SphingoTec GmbH // 16.400€

▶ Gilead Sciences GmbH // 15.000€

▶ Inflammatix // 15.000€

▶ Pfizer Pharma GmbH // 15.000€

▶ Radiometer GmbH // 15.000€

▶ Thermo Fisher Scientific // 15.000€

48 Companies & exhibitors Companies & exhibitors 49

Exhibitors

▶ bioMérieux Deutschland GmbH // 4.800€

▶ Becton Dickinson GmbH // 3.050€

▶ Biotest AG // 2.400€

▶ Biocartis N.V. // 2.400€

▶ Pascoe pharmazeutische Präparate GmbH // 2.300€

▶ CSL Behring GmbH // 1.800€

▶ ExThera Medical Europe B.V. // 1.800€

▶ FUJIFILM Wako Chemicals Europe GmbH // 1.800€

▶ Fresenius Medical Care GmbH // 1.800€

▶ InfectoPharm Arzneimittel GmbH // 1.800€

▶ MSD Sharp & Dohme GmbH // 1.800€

▶ Shionogi GmbH // 1.800€

*SIRS (systemische infl ammatorisches Response-Syndrom), auch INSI (Infection Negative Systemic Infl ammation)SeptiCyte® RAPID ist in der EU mit der CE-Kennzeichnung für IVD zertifi ziert. Immunexpress verwendet die Marke Idylla unter Lizenz von Biocartis. Der SeptiCyte® RAPID Test verwendet SuperScript™ III Reverse Transcriptase. Die Marke SuperScript III ist Eigentum der Life Technologies Corporation. Die Verfügbarkeit auf dem Markt variiert und sollte über immunexpress.com geprüft werden.

Ein Schnelltest auf Basis derPatientenimmunreaktion

Diff erenzierung zwischen Sepsisund SIRS*

Zuverlässige Ergebnisse in 1 Stunde

Vollautomatischer Prozess von der Probe bis zum Ergebnis

Weitere informationen zu Idylla™?www.biocartis.com [email protected]

Ergebnis als Wahrscheinlichkeits-Risiko-Wert (SeptiScore®)

SICHERESEPSISDIAGNOSE IN NUR EINER STUNDE


Site map Registration CateringExhibitors

Large hall

Faculty lounge DSG lounge

Terraces Terraces

Park Park

Mai

n en

tran

ce

Wing hall 1 Wing hall 2

Small hall

Tran

siti

on s

emin

ar b

uild

ing

31 30 29

967

85

4

26 23 2228 27 25 24

19

18

14

15

17

16

20

21

34

33

12

13

3

2

32

4335

1

4437 4538 4639 40 4841 4942 4736

Eastern foyer | Poster sessions


41 Becton Dickinson GmbH

15 Biocartis N.V.

17 bioMérieux Deutschland GmbH

42 Biotest AG

39 Center for Sepsis Control and Care (CSCC)

43 CSL Behring GmbH

26 Cytosorbents

28 ExThera Medical Europe B.V.

18 Fresenius Medical Care GmbH

19 FUJIFILM Wako Chemicals Europe GmbH

20 Gilead Sciences GmbH

37 Infectognostics

24 InfectoPharm Arzneimittel GmbH

30 Inflammatix

45 MSD Sharp & Dohme GmbH

14 Pascoe pharmazeutische Präparate GmbH

13 Radiometer GmbH

35 Sepsis-Stiftung

25 Shionogi GmbH

29 SphingoTec GmbH / Adrenomed AG

31 Swedish Orphan Biovitrum GmbH

In alphabetical order

Exhibitors & further sponsors

13 Radiometer GmbH

14 Pascoe pharmazeutische Präparate GmbH

15 Biocartis N.V.

17 bioMérieux Deutschland GmbH

18 Fresenius Medical Care GmbH

19 FUJIFILM Wako Chemicals Europe GmbH

20 Gilead Sciences GmbH

24 InfectoPharm Arzneimittel GmbH

25 Shionogi GmbH

26 Cytosorbents

28 ExThera Medical Europe B.V.

29 SphingoTec GmbH / Adrenomed AG

30 Inflammatix

31 Swedish Orphan Biovitrum GmbH

35 Sepsis-Stiftung

37 Infectognostics

39 Center for Sepsis Control and Care (CSCC)

41 Becton Dickinson GmbH

42 Biotest AG

43 CSL Behring GmbH

45 MSD Sharp & Dohme GmbH

Listed by booth number

ContactDeutsche Sepsis-Gesellschaft e.V.Am Klinikum 107747 Jena, Germany

▶ www.sepsis-gesellschaft.de▶ [email protected].: +49 3641 939 66 87

Foto: Sepsis Update 2019, Maik Schuck (c) weimar GmbH

www.sphingotec.com www.adrenomed.com

Precision Medicine in Septic Organ Failure: Biomarker-guided Diagnosis and Therapy

Thursday 09.09.2021 I 12:00-1:30 p.m. CEST

Chair: Prof. Dr. med. Markus Weigand

Universitätsklinikum Heidelberg

Implementing new Biomarkers in Daily Practice - Proenkephalin and biologically active Adrenomedullin in Sepsis

Priv.- Doz. Dr. med. Lukas Martin,Universitätsklinikum RWTH Aachen

Biomarker-guided Approach for the Treatment of Septic Shock - Precision Medicine in the AdrenOSS-2 Study

Prof. Dr. med. Tobias Schürholz,Universitätsklinikum RWTH Aachen Visit us

atBOOTH

29

LUNCH SYMPOSIUM

FINAL PROGRAM - sepsis-update.de

Documents

Transcript of FINAL PROGRAM - sepsis-update.de